The firm, which was founded with the opening of an Athens pharmacy in 1972 — followed by a product line called Propoline in 1979 — has up to this point made products for the domestic Greek market and about 20 export markets. Now, the aim is to develop new products tailored for specific markets like the U.S., Europe and Japan.
This means meeting consumer preferences as well as legislative regulations in each market, according to vice president and export director Alexandros Argyropoulos. While the firm has no plans to customize new formulations from scratch for each market, it intends to make variations to products based on the demands of a particular market, according to Argyropoulos.
Apivita, which takes its name from two Latin words — apis, which means bee, and vita, which means life — markets some 300 stockkeeping units across several brands, including the firm's original Propoline line, a 100-item collection of hair, oral, skin and body care products ($7-$20). There's also the 150-item Aromatherapy line, a face and body care collection that will soon be renamed Apivita ($12-$40); Express, a line of 25 masques with sales of about three million units a year ($9-$24), and Apitherapy, a brand of nutritional supplements like bee pollen ($80-$100).
The company, which had revenues of 26 million euros, or $38.3 million, in 2007, a 22 percent increase from 2006, also markets a line of hotel amenities and a roster of spa treatments.
All of Apivita's brands are being repackaged to "unify" the different lines, said Argyropoulos during a recent interview in New York. The Propoline range, which executives claim has a market share of about 40 percent in the Greek pharmacy channel on annual sales of about 600,000 bottles of shampoo alone, is slated to roll out in the U.S. with new packaging early next month.
Additionally, Apivita plans to launch outside Greece in spring a line of seven antiwrinkle and firming skin care products called Queen Bee. The line, which replaces the treatment component of the existing Aromatherapy line, will employ royal jelly and honey and will include one ingestible product. Serums and creams in the line, which are designed to stimulate the production of collagen-producing fibroblasts, will be priced from 60 euros, or $88.35, to 75 euros, or $110.45.






* Required